Boji Medical Technology Co.Ltd(300404) on January 24, the performance forecast for 2021 was released. During the reporting period, the company realized a net profit of 37-48 million yuan attributable to shareholders of listed companies, with a year-on-year increase of 117.79% – 182.54%; The net profit after deducting non recurring profits and losses was 23 million to 34 million yuan, a year-on-year increase of 133.37% to 244.99%.
In 2021, the company’s research projects were steadily promoted, and the company’s main business income increased compared with the same period of last year. It is understood that in 2021, the company obtained 14 production approvals / new drug certificates for customers, including 3 new drugs of class 1 and 4 new drugs of class 2. The company is developing more than 100 innovative drug projects in a single year, a record high.
